News Chart PharmAbcine Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 23:00:00 18/01/2024 GMT			5-day change	1st Jan Change
2,915 ^KRW	-8.91%		-.--%	-22.27%

01-24	PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors	CI
2023	PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding	CI

2.IA3n8AgU1brjSgG2AsBZoNZPMQg8UMCnXGxm_s6tqwo.f2eSnEBQvMCkCFaEaIYO5J0AZzhVHaiWZVQRmYD85UJrPJ2dQ3mP264Ocg~76e27a2953a220194a8d0119665505d3